Charles Zhu, an analyst from LifeSci Capital, maintained the Buy rating on Protara Therapeutics. The associated price target remains the same with $22.00.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Charles Zhu has given his Buy rating due to a combination of factors that highlight the potential of Protara Therapeutics’ development of IV choline chloride. The feedback from key opinion leaders (KOLs) in the field of parenteral nutrition underscores the unmet needs and clinical benefits associated with IV choline, particularly in addressing liver dysfunction linked to choline deficiency. This positions Protara’s product as a promising solution in the space, especially as the company prepares to initiate a Phase 2b/3 trial for patients with intestinal failure who rely on parenteral support.
Furthermore, the KOLs’ positive outlook on the adoption of IV choline in clinical practice suggests a favorable reception in the medical community, which could drive future demand. Despite some KOLs expressing a desire for more extensive data on morbidity and mortality outcomes, the current trial design and the potential to address significant clinical needs contribute to the optimistic view of Protara’s prospects. These elements collectively support Charles Zhu’s Buy recommendation for the stock.
According to TipRanks, Zhu is an analyst with an average return of -3.5% and a 43.55% success rate. Zhu covers the Healthcare sector, focusing on stocks such as Merus, Zymeworks, and Nuvalent.
In another report released on August 15, JonesTrading also maintained a Buy rating on the stock with a $21.00 price target.